PFO
NVAX icon

Pathstone Family Office’s Novavax NVAX Stock Holding History

Pathstone Family Office’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$112K – 1129
2020
Q4 		$112K Buy
1,000
+500
+100% +$53.1K ﹤0.01% 363
2020
Q3 		$55K Buy
500
+200
+67% +$24.4K 0.01% 356
2020
Q2 		$25K Buy
+300
New +$11.5K ﹤0.01% 400
2017
Q3 		– Sell
-250
Closed -$6K – 289
2017
Q2 		$6K Hold
250
– – ﹤0.01% 339
2017
Q1 		$6K Buy
+250
New +$6.88K ﹤0.01% 316

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pathstone Family Office's NVAX Position: Q1 2021 in Review

Pathstone Family Office sold out of Novavax (NVAX) in Q1 2021, closing a stake of 1,000 shares — an estimated $112K sold.

Pathstone Family Office first reported a position in NVAX in Q1 2017 and held it in 5 quarters. The position peaked at $112K in Q4 2020. 389 funds tracked by Wall St. Rank hold NVAX as of Q1 2021.

  • Pathstone Family Office reported no remaining Novavax position as of Q1 2021 after selling out during the quarter.
  • Pathstone Family Office sold 1,000 Novavax shares in Q1 2021, an estimated $112K.
  • Pathstone Family Office first reported a position in Novavax in Q1 2017 and held it in 5 quarters.
  • Pathstone Family Office's Novavax position peaked at $112K in Q4 2020.
  • 389 funds tracked by Wall St. Rank held Novavax as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.